, /PRNewswire/ -- The global dry eye syndrome drugs market size is estimated to grow by .13 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 6.
16% during the forecast period. Growing geriatric population is driving market growth, with a trend towards advancements in drug delivery technologies. However, less visibility into reimbursement of ophthalmic disorder treatments poses a challenge.
Key market players include Abbott Laboratories, AbbVie Inc., AFT Pharmaceuticals Ltd., Akorn Operating Co LLC, Bausch Health Companies Inc.
, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, I MED Pharma Inc.
, Johnson and Johnson Services Inc., Laboratoires Thea, Mitotech SA, Novaliq GmbH, Novartis AG, Oasis Medical Inc., Otsuka Holdings Co.
Ltd., Santen Pharmaceutical Co. Ltd.
, Sentiss Pharma Pvt. Ltd., Sun Pharmaceutical Industries Ltd.
, Viatris Inc., and Visufarma. Get a detailed analysis on regions, market segments, customer landscape, and companies- Dry eye syndrome drugs market is witnessing significant growth due to advancements in drug delivery technologies.
These innovations include lipid-based formulations that mimic natural tears, sustained release systems for controlled drug delivery, and nanotechnology-based approaches for targeted drug delivery. These advancements offer improved therapeutic outcomes, increased patient comfort, and enhanced treatment adherence, addressing challenges of traditional eye drops such as low bioavailabi.
